Illustration: Lindsey Bailey/Axios
Pfizer signed a deal worth up to $10.5 billion to develop cancer drugs with Chinese biotech Innovent Biologics, the companies announced Friday.
The big picture: China's drugmaking gains are pushing U.S. biotechs to either compete harder — or partner up.
